Publications by authors named "Kozo Kuribayashi"
Introduction: In August 2018, the Japanese PMDA approved nivolumab, an immune checkpoint inhibitor (ICI), for previously treated, unresectable, advanced, or recurrent pleural mesothelioma (PM) based on the MERIT trial, a phase II study of 34 cases. However, concerns regarding limited evidence persist.
Methods: We retrospectively analyzed 83 patients with previously treated, unresectable, advanced, or recurrent malignant pleural mesothelioma (MPM) treated with nivolumab from August 2018 to May 2022.
Article Synopsis
- The hemagglutinating virus of Japan envelope (HVJ-E) is an inactivated virus that has shown promise in treating chemotherapy-resistant malignant pleural mesothelioma (MPM) by inducing antitumor immunity.
- A phase I clinical study focused on determining a suitable dosage and evaluating the preliminary efficacy of HVJ-E, finding that higher doses resulted in better disease control rates compared to lower doses.
- The study concluded that HVJ-E is safe for patients and appears to have some antitumor activity, leading to plans for a phase II trial with higher dosages.
In February 2004, the Food and Drug Administration (FDA) was the first to approve the combination of cisplatin (CDDP) and pemetrexed (PEM) as standard first-line chemotherapy for untreated, unresectable malignant pleural mesothelioma (MPM). However, after that approval, no progress was made in the standard first-line treatment of MPM for almost 15 years. Positive results from a phase 3 study (Mesothelioma Avastin Cisplatin Pemetrexed Study: MAPS) verifying the effect of bevacizumab, an anti-angiogenesis agent added to CDDP/PEM for unresectable MPM, were published in The Lancet in December 2015; however, this did not lead to approval by national drug regulatory agencies.
View Article and Find Full Text PDFBackground: In clinical practice, peritoneal dissemination after curative-intent surgery for pleural mesothelioma occasionally recurs. This study investigated the risk factors and prognosis associated with post-pleurectomy/decortication peritoneal dissemination in pleural mesothelioma, which are rarely reported.
Methods: This retrospective review included 160 patients who experienced recurrence after pleurectomy/decortication for pleural mesothelioma between January 2011 and December 2021.
Article Synopsis
- The study compared the effectiveness of two response evaluation methods (imPERCIST and mRECIST) in patients with malignant pleural mesothelioma after receiving nivolumab plus ipilimumab immunotherapy.
- Results showed that imPERCIST identified a higher percentage of complete metabolic responses compared to mRECIST, while both methods demonstrated a high level of agreement.
- Overall survival and progression-free survival were significantly longer in patients who showed improvement, emphasizing the importance of accurate tumor response evaluation for prognosis prediction.
Article Synopsis
- This study examines the survival rates of pleural mesothelioma patients who either underwent surgery after neoadjuvant chemotherapy or refused surgery entirely.
- A total of 296 eligible patients were analyzed, with 272 choosing surgery and 24 refusing; the results indicated that those who had surgery experienced significantly better overall survival (40.7 months) and progression-free survival (20.2 months) compared to those who refused surgery (23.6 months and 12.9 months, respectively).
- The findings suggest that surgical intervention may significantly enhance survival outcomes for patients diagnosed with pleural mesothelioma.
Article Synopsis
- The paper addresses the challenge of prognosis prediction for rare diseases, specifically malignant pleural mesothelioma (MPM), by using a multimodal deep learning (DL) approach that combines limited 3D PET/CT images with clinical data to enhance predictive accuracy.
- A unique 3D convolutional conditional variational autoencoder (3D-CCVAE) is employed to reduce the dimensionality of PET images, while also leveraging clinical data to prevent overlearning and optimize efficiency in the prediction process.
- The study involved training multiple models on data from 520 MPM patients, comparing the performance of the 3D-CCVAE model against variations without key mechanisms, and measuring outcomes using
Article Synopsis
- Malignant pleural mesothelioma (MPM), a deadly cancer linked to asbestos, has seen limited effective treatments, but combining ipilimumab and nivolumab shows promise for better patient outcomes.
- Researchers evaluated whether nintedanib, an antiangiogenic drug, could enhance the effects of the anti-PD-1 antibody; while it wasn't effective in stopping cell growth in lab tests, it significantly reduced tumor growth in mouse models.
- Nintedanib was found to decrease tumor-associated macrophages that promote tumor growth, while also altering their function, and when combined with anti-PD-1 therapy, it helped reactivate the immune response against mesothelioma cells.
Article Synopsis
- The study assessed the effectiveness and safety of nivolumab and ipilimumab for treating recurrent malignant pleural mesothelioma (MPM) after initial surgery.
- In a trial with 41 patients, the results showed a 43.9% objective response rate (ORR) and a 75.6% disease control rate (DCR) with some patients experiencing serious side effects.
- Despite the promising outcomes, including a 74.2% post-treatment survival rate over 12 months, the occurrence of serious adverse events indicates that caution is needed in treatment application.
Background: There is no authorized treatment for malignant non-pleural mesothelioma (MNPM) worldwide. In contrast to malignant pleural mesothelioma, MNPM has not been investigated, and no treatment has been established due to its rarity.
Objectives: This multicenter, open-label, single-arm, Japanese phase II trial aims at evaluating the efficacy and safety of nivolumab, an immune checkpoint inhibitor, in advanced or metastatic MNPM treatment.
Background/aim: Malignant peritoneal meso-thelioma (MPeM) has no specific imaging findings that can distinguish it from other peritoneal tumors and the accuracy of peritoneal cytology is low, therefore definitive diagnosis is usually performed by histology. This study investigated whether F-fluorodeoxyglucose positron emission tomography/ computed tomography representing glucose metabolism is a useful modality for identifying biopsy sites using the tumor viability of MPeM.
Patients And Methods: Sixty MPeM patients underwent pre-biopsy FDG-PET/CT examination.
Article Synopsis
- This study investigates residual thoracic spaces (RTS) after pleurectomy/decortication (P/D) in patients with malignant pleural mesothelioma over a 3-month period post-surgery.
- Out of 170 patients, 34.1% were identified with RTS, where prolonged postoperative air leak (>7 days) emerged as a key risk factor for developing RTS.
- The findings indicate that while some patients recover from RTS, others may require additional medical interventions, highlighting the need for monitoring in the postoperative phase.
Objective: To determine whether results of a standardized uptake value (SUV)-based semi-quantitative analytic method for gallium-67 (Ga)-citrate single photon emission tomography/computed tomography (SPECT/CT) reflects disease activity in patients with interstitial lung disease.
Subjects And Methods: Gallium-67-citrate SPECT/CT was used to evaluate disease activity in 24 patients with interstitial pneumoniaon clinical grounds at a single institution from June 2018 to August 2020. SUV in a given volume of interest over the bilateral pulmonary parenchyma was calculated using a dosimetry software package.
Article Synopsis
- The study aimed to compare three imaging methods—F-FDG PET (using EORTC and PERCIST criteria) and CT (using RECIST1.1)—to assess treatment response and predict outcomes in non-small-cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitors.
- It involved 40 NSCLC patients who underwent imaging before and after treatment, with the response rates for EORTC and PERCIST showing strong alignment (92.5%), but weaker concordance with RECIST1.1 (65% for both comparisons).
- Results indicated that patients without disease progression based on both PET and CT had significantly longer progression-free survival (PFS) and overall survival (OS), with certain metrics on scans being
Background/aim: To evaluate the incidence and grade of radiation pneumonitis after volumetric modulated arc therapy (VMAT) performed for the treatment of non-small cell cancer (NSCLC).
Patients And Methods: Fifty consecutive non-surgical candidates with NSCLC underwent VMAT. Thirty-five patients had stage-III tumors and 15 had recurrent tumors.
Objectives: This study analyzed an artificial intelligence (AI) deep learning method with a three-dimensional deep convolutional neural network (3D DCNN) in regard to diagnostic accuracy to differentiate malignant pleural mesothelioma (MPM) from benign pleural disease using FDG-PET/CT results.
Results: For protocol A, the area under the ROC curve (AUC)/sensitivity/specificity/accuracy values were 0.825/77.
Background: Malignant pleural mesothelioma (MPM) has few treatment options. Pembrolizumab showed preliminary clinical benefit in programmed death ligand 1 (PD-L1)-positive MPM. We evaluated the efficacy and safety of pembrolizumab monotherapy in patients with previously treated MPM irrespective of PD-L1 status in the KEYNOTE-158 study.
View Article and Find Full Text PDFArticle Synopsis
- The study compares FDG-PET criteria (EORTC, PERCIST, imPERCIST) with CT criteria for evaluating therapy response and predicting prognosis in recurrent MPM patients on ICI monotherapy.
- Thirty MPM patients were assessed with both FDG-PET/CT and contrast-enhanced CT during treatment, and different response categories were generated.
- Results indicated high concordance among FDG-PET criteria and showed that these criteria were generally more effective at predicting progression-free survival (PFS) compared to CT criteria, with imPERCIST achieving the best predictions.
Usefulness of Quantitative Bone Single-Photon Emission Computed Tomography/Computed Tomography for Evaluating the Treatment Response of Bone Metastasis in a Lung Cancer Patient.
Case Rep Oncol
March 2021
We report a case of bone metastasis arising from lung cancer, including quantitative values obtained with bone single-photon emission computed tomography/computed tomography (SPECT/CT), which were useful to evaluate the treatment response. The first bone SPECT/CT during pembrolizumab therapy for lung cancer recurrence showed intense Tc-HMDP uptake of the right femur head and mild uptake of the left ribs. After the palliative radiotherapy for the right femur head metastasis and chemotherapy, the second bone SPECT/CT showed a decrease in focal uptake of the right femur hip and increasing uptake of the left ribs.
View Article and Find Full Text PDFMalignant pleural mesothelioma (MPM) is strongly associated with occupational or environmental asbestos exposure and arises from neoplastic transformation of mesothelial cells in the pleural cavity. The only standard initial treatment for unresectable MPM is combination chemotherapy with cisplatin (CDDP) and pemetrexed (PEM). Further, CDDP/PEM is the only approved regimen with evidence of prolonged overall survival (OS), although the median OS for patients treated with this regimen is only 12 months after diagnosis.
View Article and Find Full Text PDFBackground: A few studies have reported the incidence and clinical implications of complications after pleurectomy/decortication (P/D).
Objective: The aim of this study was to assess the details of complications and predictive factors of particularly durable air leak with P/D.
Methods: Data on 163 consecutive patients who underwent neoadjuvant chemotherapy (NAC) followed by P/D for malignant pleural mesothelioma between September 2012 and May 2020 at our institution were retrospectively analyzed.
Background: Cisplatin-pemetrexed combination chemotherapy is the current standard primary treatment for malignant pleural mesothelioma (MPM). It was first approved for untreated and unresectable MPM in the 2003 National Comprehensive Cancer Network (NCCN) guidelines. However, to date, standard treatments for patients with MPM who previously underwent chemotherapy, as recommended by the NCCN Malignant Pleural Mesothelioma guidelines, have been inadequate.
View Article and Find Full Text PDFAims: Malignant pleural mesothelioma (MPM) is an aggressive malignancy with poor prognosis and limited treatment options. Cisplatin plus pemetrexed is the only approved first-line treatment for patients with unresectable MPM. Recently, promising outcomes were observed with first-line bevacizumab combined with cisplatin/pemetrexed, leading to the recommendation of this regimen as a first-line treatment option for patients with MPM.
View Article and Find Full Text PDFMalignant pleural mesothelioma (MPM) is an asbestos-related aggressive malignant neoplasm. Due to the difficulty of achieving curative surgical resection in most patients with MPM, a combination chemotherapy of cisplatin and pemetrexed has been the only approved regimen proven to improve the prognosis of MPM. However, the median overall survival time is at most 12 mo even with this regimen.
View Article and Find Full Text PDF